Hepatology Research
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis
Hepatology Research, Volume 52, Issue 3, Page 308-316, March 2022.
Hepatology Research
Issue Information
Hepatology Research, Volume 52, Issue 3, Page 225-226, March 2022.
Hepatology Research
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease
Hepatology Research, Volume 52, Issue 3, Page 317-319, March 2022.
Hepatology Research
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis
Hepatology Research, Volume 52, Issue 3, Page 269-280, March 2022.
Hepatology Research
ATF2 accelerates the invasion and metastasis of hepatocellular carcinoma through targeting the miR‐548p/TUFT1 axis
Hepatology Research, Volume 52, Issue 3, Page 281-297, March 2022.
Hepatology Research
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy
Hepatology Research, Volume 52, Issue 3, Page 298-307, March 2022.
Hepatology Research
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era
Hepatology Research, Volume 52, Issue 3, Page 247-254, March 2022.
Hepatology Research
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis
Hepatology Research, Volume 52, Issue 3, Page 235-246, March 2022.
Hepatology Research
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension
Hepatology Research, Volume 52, Issue 3, Page 255-268, March 2022.